Treatment of chronic hepatitis B in China

Journal of Gastroenterology and Hepatology (Australia)

Volumn 15, Issue SUPPL. MAY, 2000, Pages

  Yao, Guang Bi ^a,b  

^a Shanghai Jing An Qu Central Hospital   (China)

^b NONE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BICYCLOLAM; BIFENIDATE; GLYCYRRHIZIC ACID; HEPATITIS B SURFACE ANTIGEN TRANSFACTOR; HEPATITIS B VACCINE; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; HERBACEOUS AGENT; IMMUNOMODULATING AGENT; INTERFERON; LAMIVUDINE; LIVER PROTECTIVE AGENT; LYMPHOBLAST INTERFERON; MARINE; MATRINE; NUCLEOSIDE DERIVATIVE; PREDNISOLONE; PREDNISONE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA1B INTERFERON; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VIRUS DNA;

ANTIBIOTIC THERAPY; ANTIBODY TITER; ANTIVIRAL ACTIVITY; CHINA; CHINESE MEDICINE; CLINICAL TRIAL; CONFERENCE PAPER; DRUG CHOICE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG SCREENING; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION RATE; MORTALITY; NONHUMAN; PHYLLANTHUS; PRIORITY JOURNAL; RELAPSE; SEROCONVERSION; TREATMENT OUTCOME; VACCINATION; VIREMIA;

EID: 0033948876     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.2000.02106.x     Document Type: Conference Paper

References (23)

1. Dai ZE, Qi GM. Viral hepatitis in China. In: Seroepidemiological Survey in Chinese Population. Beijing: Science & Technology Archive Publications, 1997; 39-59.
2. Yao GB, Zhang LM, Fei GZ et al. Recombinant alpha 2b intron A in the treatment of chronic hepatitis B. Chin. J. Gastroenterol. 1991; 11: 133-6.
3. Ji YY, Yao GB, Sun RY A pharmacokinetic study of two formulations of recombinant interferon alpha α2a in healthy Chinese volunteers. Chin. J. Clin. Pharmacol. 1999; 15: 123-5.
4. Xiong SS, Yao GB, Xu DZ et al. A clinical study on treatment of chronic viral hepatitis B using domestic recombinant human interferon alpha-1. Chin. J. Gastrenterol. 1995; 194-7.
5. Zou SB, Zhang DF, Zhao YR et al. A comparative study of recombinant interferon α1 and α2b in treatment of chronic hepatitis. Chin. J. Hepatol. 1994; 2: 180-2.
6. Qiu WL, Li FY, Cui XL et al. Response to recombinant interferon treatment and its influencing factors in patients with anti-HBe positive chronic hepatitis B. Chin. J. Hepatol. 1998; 6: 218-20.
7. Ha ZY, Li GH, Liu BD, Zhu M. The followe-up study of 91 cases of chronic hepatits B treated with IHNα1b. Bull. Nan Jing Med. Univ. 1999; 19: 67-9.
8. Joang YS, Yao JL, Deng LX et al. The clinical effect on the inhibition of HBV replication in CHB patients treated with recombinant interferon. Guangdong Med. J. 1995; 16: 794-6.
9. Lu HY, Wang R, Cao YL. Clinical efficacy of interferon α2b (intron A) in treatment of chroinic hepatitis B. Guangdong Med. J. 1998; 19: 790-1.
10. He NH, Gu ZH, Hu DR et al. Longterm follow-up study on the efficacy of IFN α2b in the treatment of chronic hepatits B. Chin. J. Hepatol. 1996; 4: 33-6.
11. Lu J, Yang SS, Ao FJ, Zhou BH. Interferon treatment in 43 cases of children with chronic hepatitis B. Pract. Clin. Pediatr. J. 1999; 14: 3-4.
12. Liu DK, Wen XF, Meng QH et al. Efficacy of interferon α-n1 in treatment of chronic hepatitis B. Chin. J. Exp. Clin. Virol. 1998; 12: 125-8.
13. Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD. A randomized double-blind placebo-controlled study of lamivudine in the treatment of patients with chronic hepatitis B virus infection. Chin. Med. J. 1999; 112: 387-91 (English Edn).
14. Yao GB, Wang BE, Cui ZY, Yao JL, Zeng MD. Long-term effect of lamivudine treatment in chronic hepatitis virus B infection. Chin. J. Hepatol. 1999; 7: 80-3.
15. Wang BE, Yu CZ, Tien GS et al. Treatment of chronic hepatitis B with thymosin-αl. Exp. Chin. Hepatol. 1997; 26: 626A.
16. Lu ZM, Yao GB, Wu XH et al. A comparative trial of thymosin α1 vs thymosin-α1 combined with interferon-α1 in the treatment of chronic hepatitis B. Chin. J. Infect. Dis. 1999; 17: 24-7.
17. Ji YY, Yao GB, Wang FZ et al. The effect of HBsAg transfer factor on specific cellular immune response. Shanghai Immunol. J. 1997; 17: 374-6.
18. Yao GB, JiYY, Xu DZ et al. Phase I and II clinical trial of HBsAg transfer factor in the treatment of chronic hepatitis B. Chin. J. Clin. Pharmacol. Ther. 1999; 4: 1-4.
19. Wang BS. Current status of Chinese traditional medicine in treatment of chronic hepatitis B. CTM Res. 1995; 8: 43-7.
20. Zou SJ, Li JA, Pan PR. Immunology mechanism and clinical application of glycyrrhizin in treatment of chronic viral hepatitis. Clin. J. Integr. Trad. West. Med. Liver Dis. 1992; 2: 50-4.
21. Wu SM, Jiang J, Wu JJ, Ma ZQ, He MH. Intravenous matrine in treatment of chronic hepatitis B. Clin. J. Integr. Trad. West. Med. Liver Dis. 1991; 1: 1-2.
22. Wan YS, Zhong CG. The effect of Phyllanthus amarus in HBsAg carriers. Clin. J. Integr. Trad. West. Med. Liver Dis. 1991; 1: 38-9.
23. Dong ZH, Zhong YX. Current research on Schisandra and bifendate in treatment of hepatitis. Clin. J. Integr. Trad. West. Med. Liver Dis. 1991; 1: 51-3.